FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report

2018 ◽  
Vol 74 ◽  
pp. 114-121 ◽  
Author(s):  
Koping Chang ◽  
Jia-Hau Liu ◽  
Shan-Chi Yu ◽  
Chung-Wu Lin
2013 ◽  
Vol 131 (3) ◽  
pp. 198-204 ◽  
Author(s):  
Pedro Pinto-Lopes ◽  
Francisco Adao Fonseca ◽  
Roberto Silva ◽  
Pedro von Hafe ◽  
Elsa Fonseca

CONTEXT Systemic mastocytosis is defined as a clonal disorder of mast cells and their precursor cells and is currently classified as a myeloproliferative neoplasm. Its clinical course has a wide spectrum, ranging from indolent disease, with normal life expectancy, to highly aggressive disease, associated with multisystemic involvement and poor overall survival. The aim of this study was to report a case of indolent systemic mastocytosis, focusing on the diagnostic challenges, with a review of the literature. CASE REPORT A 79-year-old Caucasian woman with osteoporosis was evaluated at the Emergency Department because of complaints of low back pain. Before this, she had consulted an orthopedist and had undergone some imaging examinations, namely a bone scan that revealed a “superscan” pattern. Due to her pain complaints and these test results, the patient was admitted to the Department of Internal Medicine. After undergoing several analytical tests and some additional imaging examinations to rule out some important differential diagnoses, she then underwent bone marrow biopsy, which made it possible to identify indolent systemic mastocytosis. CONCLUSION Systemic mastocytosis is a rare entity that is difficult to diagnose. Its symptoms are often unspecific and frequently ignored. Skeletal changes may be the first and only manifestation of the disease and in some cases, like this one, the diagnosis is made only after histological examination. The key point for the diagnosis is to contemplate the possibility of systemic mastocytosis.


2018 ◽  
Vol 02 (01) ◽  
Author(s):  
Margaret L Musser ◽  
Kayden E Toone ◽  
Erika P Berger ◽  
Austin K Viall ◽  
Leslie E Fox ◽  
...  

2015 ◽  
Vol 72 (4) ◽  
pp. 383-385 ◽  
Author(s):  
Radmila Zivkovic ◽  
Olivera Markovic ◽  
Dragomir Marisavljevic ◽  
Tatjana Terzic ◽  
Ljiljana Tukic

Introduction. Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm that occurs most commonly in the decade six of life and it is very rare in the young persons. Case report. We reported a 28-year-old female patient with primary myelofibrosis who had a normal pregnancy and delivery in the week 40 of pregnancy without any complications. Two years before the diagnosis of PMF she had normal pregnancy. The patient was treated with interferon-alpha and low dose aspirin during the whole pregnancy and with low-molecular-weight heparin a week before delivery and 6 weeks after. The patient had no complications during pregnancy. She delivered in term with healthy, normal baby weight. Conclusion. Decision about treatment strategy of pregnancy associated hematologic malignancies should be made for each patient individually.


2021 ◽  
Vol 10 (3) ◽  
pp. 1603-1608
Author(s):  
Jiuju Wang ◽  
Shanshan Jiang ◽  
Qiaojiajie Zhao ◽  
Xucang Wei ◽  
Wensheng Li

2019 ◽  
Vol 12 (4) ◽  
pp. e227768
Author(s):  
Daniel Steven Sanders ◽  
Thomas Fennell ◽  
Mohammad Muhsin Chisti

A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat bone marrow biopsy to assess haematological response after 6 months of initial lenalidomide therapy. Subsequent bone marrow biopsies revealed persistent MDS with del(5q) in addition to a small atypical mast cell population with >25% of mast cells with spindle-shaped morphology and immunohistochemistry characteristics consistent with mastocytosis. Molecular testing on the bone marrow was positive for cKIT D816V and the patient was diagnosed with systemic mastocytosis (SM) with an associated haematological neoplasm. MDS with SM is well known to be associated; however, to the best of our knowledge, only one prior case report identifies MDS with del(5q) and associated cKIT D816V positive mastocytosis. While the exact clonal origin of both chromosomal aberrations is unclear, this case illustrates the therapeutic efficacy of lenalidomide in a patient with MDS with del(5q) and rarely associated cKIT positive SM.


2019 ◽  
Vol 74 (6) ◽  
pp. 844-848
Author(s):  
Keisuke Maruyama ◽  
Naoki Nakagawa ◽  
Ayana Suzuki ◽  
Maki Kabara ◽  
Motoki Matsuki ◽  
...  

Rheumatology ◽  
2019 ◽  
Vol 58 (Supplement_3) ◽  
Author(s):  
Siwalik Banerjee ◽  
Shanmugam Saravana

Sign in / Sign up

Export Citation Format

Share Document